Skip to main content

Table 1 Multivariate analysis of serum biomarkers and overall survival in stage III-IV melanoma patients

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

 Training setIndependent validation set
Patients Patients 
N%%
Dead
HR95% CIPN%%
Dead
HR95% CIP
S100A8/A9
 ≤ 5.5 mg/l8171.135.81  17070.822.41  
 > 5.5 mg/l3328.969.72.741.37–5.46.00437029.245.71.791.06–3.02.030
S100B
 ≤ 0.1 μg/l8070.235.01  19079.218.41  
 > 0.1 μg/l3429.870.61.610.75–3.43.225020.870.03.311.82–6.03<.0001
LDH
 ≤ ULN8473.740.51  20585.425.41  
 > ULN3026.360.01.680.68–4.12.263514.651.41.350.72–2.54.35
  1. NOTE. Multivariate survival analysis included 114 AJCC stage III and stage IV patient cases in the training set, and 240 AJCC stage III and stage IV patient cases in the independent validation set. The models were adjusted for age, sex, and clinical stage
  2. Abbreviation: CI confidence interval, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value, ULN upper limit of normal